# 510(k) Summary of Safety and Effectiveness

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, Address, and Contact

Lin-Zhi International. Inc. 670 Almanor Avenue Sunnyvale, CA 94085 Phone: (408) 732-3856 Fax: (408) 732-3849 e-mail: bclin@lin-zhi.com

Contact

Bernice Lin, Ph D. VP Operations

# Device Name and Classification

Classification Name:

Methamphetamine Test System Class II, LAF (91 Toxicology). 21 CFR 862.3610

Drug Specific Calibrators, Class II. DLJ (91 Toxicology). 21 CFR 862.3200

Drug Specific Controls, Class I, LAS (91 Toxicology). 21 CFR 862.3280

# Common Name: Proprietary Name:

Homogeneous Methamphetamine Enzyme Immumoassay LZI Methamphetamine Enzyme Immunoassay. LZI Methamphetamine Drugs of Abuse (DAU) Calibrators LZI Methamphetamine Drugs of Abuse (DAU) Controls

# Legally Marketed Predicate Device(s)

The LZI Methamphetamine Enzyme Immunoassay (ELA) at a cutoff of 500 ng/mL i substantially equivalent to the Amphetamines 500 Enzyme Immumoassay and Amphetamine 500 Calibrators and Controls for Hitachi 717 Systems (k102210) mamufactured by Lin-Zh Intemational, Inc with a cutoff of $5 0 0 \approx 2 0 0 0$ . The LZI Methamphetamine Enzym Immumnoassay is identical or similar to its predicate in terms of intended use, method principle device components, and clinical performance.

# Device Description

The LZI Methamphetamine Enzyme Immunoassay is a homogeneous enzyme immmunoassa! with ready-to-use liquid reagent. The assay is based on competition between drug in th sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for : fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to th antibody, and the drug concentration in the sample is measured in terms of enzyme activity. I the absence of drug in the sample, methamphetamine-labeled G6PDH conjugate is bound t antibody, and the enzyme activity is inhibited. On the other hand, when free drug is present i the sample, antibody would bind to free drug. the umboumd methamphetamine-labeled G6PDl then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenin dimucleotide (NAD) to NADH, resulting in an absorbance change that can be measure spectrophotometrically at $3 4 0 \ m$ .

The LZI Methanphetamine Enzyme Immmoassay is a kit comprised of two reagents, an R and $\mathbf { R } _ { 1 }$ which are bottled separately but sold together within the kit.

The $\mathbf { R _ { l } }$ solution contains mouse monoclonal anti-methamphetamine antibody, glucose-6 phosphate $( \ G \theta \mathbf { P } )$ nicotinamide adenine dinucleotide (NAD), stabilizers, and sodium azid $( 0 . 0 9 \% )$ as a preservative. The $\pmb { \mathrm { R } _ { \lambda } }$ solution contains glucose-6-phosphate dehydrogenas (G6PDH) labeled with d-methamphetamine in buffer with sodium azide $( 0 . 0 9 \% )$ a preservative.

The LZI Methamphetamine Enzyme Immunoassay calibrators and controls designated for use at the $5 0 0 \approx \mathrm { { m g / m l } }$ cutoff contain 0, 250, 375, 500, 625, 1000, and $2 0 0 0 \approx \mathrm { m g / m L }$ of dmethamphetamine in human urine with sodium azide $( 0 . 0 9 \% )$ as preservative. These five calibrators and two controls are sold as individual bottles.

# Intended Use

The LZI Methamphetamine Enzyme Immunoassay is intended for the qualitative and semiquantitative determination of d-methamphetanine in human urine, at a cutoff value of 500 $\approx / \equiv$ . The assay is designed for professional use with a number of automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS and LCMS or (2) permitting laboratories to establish quality control procedures.

The LZI Methanphetamine Drugs of Abuse (DAU) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the Methamphetamine Enzyme Immnoassay at a cutoff value of $5 0 0 \bar { \cdot } \bar { \bf n } \bar { \bf g } / \bar { \bf m L }$ .

The LZI Methamphetamine Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the Methamphetamine Enzyme Immunoassay at a cutoff value of $5 0 0 \approx \mathrm { \Omega } ^ { \mathrm { / m i } }$ .

The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or liquid chromaiography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method). Clinical consideration and professional judgment should be exercised with any drug of abuse iest resul, particularly when the preliminary test result is positive.

# Comparison to Predicate Device

The Lin-Zhi Intemational, Inc. (LZI) Methamphetamine Enzyme Immunoassay used at the 500 ng/mL cutoff is substantially equivalent to the Lin-Zhi International, Inc. Amphetamines 500 Enzyme Immumoassay, Calibrators and Controls for Hitachi 717 Systems cleared by the FDA under the premarket notification k102210 for its stated intended use.

The following table compares LZI's Methamphetamine Enzyme Immunoassay at the 500 ng/mL cutoff with the predicate device.

<table><tr><td rowspan=1 colspan=1>DeviceCharacteristics</td><td rowspan=1 colspan=1>Subject DeviceLZI Methamphetamine EnzymeImmunoassay</td><td rowspan=1 colspan=1>Predicate Device (k102210)Amphetamines 500 EnzymeImmunoassay, Calibrators and Controls</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The LZI Methamphetamine EnzymeImmumoassay, when used in conjumctionwith Hitachi 717 automated clinicalsystem analyzers, is intended for thequalitative and semi-quantitativedeterination of methamphetamine inhuman urine, af a cutoff valne of 500ng/ml. The assay is designed forprofessional use with a mumber ofautomated clinical chemistry analyzers.Thi assgy prorides a rapid screening procedurefor deiermining the presence of d-methamphaimine in urine. The assay providesonhy a preliminary anahtical reanht A marespecific alternative chemical method mnd be uiedin orden to obtain a conftrmed eralytical resultGas or iquid chromatography/mass spectromety(GCMS an LCAiS) in the preferred confrmatrymathod Chnical considrretion and prefessionchjudgment should be cxurcined with any drug ofabuse usi resnl, paraicalarhy when the preliminarytest result i positive.</td><td rowspan=1 colspan=1>The Amphetamines $00 EnzymeImmmmoassay from Lin-Zhi International,Inc., when used in conjunction withHitachi 717 automated clinical systemanalyzers is intended for the qualitativeand semi-quantitative determination ofamphetamine and methamphetamine inhuman urine, at a cutoff valne of 500ng/mL. The assay is designed forprofessional use with a number ofautomated chinical chemistry analyzers.This assay provides a rapid screening procesurefor determining the preseace of d-methampheicmins and d-ompheromine in urine.The esscy provides only a prefiminary anahtirdlreoah A more specific ahernarive chemicalmathod mrst be ased in ordat to obain Gconfirmed aralyrical resuh Gos or liquidchromsiogaphy/man spectromeiry (GC/M1S orLCAMS) is the prefered confermaiory method.Clinical consideration and prafessional judymentshould be exercised with ony drug of abuse tesiresal, particularty when the preliminary est resullin posinine.</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>d-methamphetamine</td><td rowspan=1 colspan=1>d-methamphetamine &amp;d-amphetamine</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>500 ng/ml</td><td rowspan=1 colspan=1>500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Urine</td></tr><tr><td rowspan=1 colspan=1>CalibratorsLevel</td><td rowspan=1 colspan=1>5 Levels(0, 250, 500, 1000, 2000 ng/mL)</td><td rowspan=1 colspan=1>5 Levels(0, 250, 500, 1000, 2000 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Controls Level</td><td rowspan=1 colspan=1>2 Levels(375 ng/mL. 625 ng/mL)</td><td rowspan=1 colspan=1>2 Levels(375 ng/mL. 625 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8 °C until expiration date</td><td rowspan=1 colspan=1>2-8 °C until expiration date</td></tr></table>

# Performance Characteristics Summary: Hitachi 717 Analyzer

Precision: Precision: Semi-Quantitative, ng/mL

Semi-Quantitative Precision Analysis Sunimary: Qualitative Results   

<table><tr><td rowspan=2 colspan=1>N=83(ng/mL)</td><td rowspan=1 colspan=3>Within Run</td><td rowspan=1 colspan=3>Total Precision</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>% CY</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>% CT</td></tr><tr><td rowspan=1 colspan=1>0 ag/mL</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>4.82</td><td rowspan=1 colspan=1>87.5%</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>91.6%</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>112.3</td><td rowspan=1 colspan=1>2.74</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>112.3</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>250 ng/mL</td><td rowspan=1 colspan=1>249.6</td><td rowspan=1 colspan=1>2.79</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>249.6</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>387.1</td><td rowspan=1 colspan=1>4.57</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>387.1</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>1.4%</td></tr><tr><td rowspan=1 colspan=1>$00 ng/mL</td><td rowspan=1 colspan=1>513.5</td><td rowspan=1 colspan=1>6.05</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>513.5</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=1 colspan=1>625 ng/mL</td><td rowspan=1 colspan=1>635.6</td><td rowspan=1 colspan=1>7.47</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>635.6</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1>750 ng/mL</td><td rowspan=1 colspan=1>751.0</td><td rowspan=1 colspan=1>8.14</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>751.0</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=1 colspan=1>875 ng/mL</td><td rowspan=1 colspan=1>$68.4</td><td rowspan=1 colspan=1>11.90</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>86S.4</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=1 colspan=1>1000 ng/mL</td><td rowspan=1 colspan=1>987.7</td><td rowspan=1 colspan=1>11.25</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>987.7</td><td rowspan=1 colspan=1>15.2</td><td rowspan=1 colspan=1>1.5%</td></tr></table>

<table><tr><td rowspan=2 colspan=1>N=83(ngmL)</td><td rowspan=1 colspan=2>Within Rup</td><td rowspan=1 colspan=2>Total Precition</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Qualitative Response</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Qualitative Response</td></tr><tr><td rowspan=1 colspan=1>0ug/mL</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>:</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>125 ag/mL</td><td rowspan=1 colspan=1>112.3</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>112.3</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>250 ng/mL</td><td rowspan=1 colspan=1>249.6</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>249.6</td><td rowspan=1 colspan=1>*</td></tr><tr><td rowspan=1 colspan=1>375 ag/mL</td><td rowspan=1 colspan=1>387.1</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>387.1</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>500 ng/iml</td><td rowspan=1 colspan=1>513.5</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>513.5</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>625 ng/mL</td><td rowspan=1 colspan=1>635.6</td><td rowspan=1 colspan=1>÷</td><td rowspan=1 colspan=1>635.6</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>750 ag/mL</td><td rowspan=1 colspan=1>751.0</td><td rowspan=1 colspan=1>÷</td><td rowspan=1 colspan=1>751.0</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>875 ng/mL</td><td rowspan=1 colspan=1>868.4</td><td rowspan=1 colspan=1>†</td><td rowspan=1 colspan=1>868.4</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>1000 ng/mL</td><td rowspan=1 colspan=1>987.7</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>987.7</td><td rowspan=1 colspan=1>+</td></tr></table>

# Semi-Quantitative Positive/Negative Results:

<table><tr><td rowspan=1 colspan=2>500 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SampleConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/inL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>125 ng/nL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>250 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>375 ag/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>85 Pos/ 3 Neg</td></tr><tr><td rowspan=1 colspan=1>625 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>750 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>875 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>1000 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

# Performance Characteristies Summary: continued Hitachi 717 Analyzer

Precision: Qualitative, mA/min

<table><tr><td rowspan=2 colspan=1>N=S8(mA/min)</td><td rowspan=1 colspan=3>Within Run</td><td rowspan=1 colspan=3>Total Precision</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>% CY</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>% CV</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>92.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>92.6</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.1%</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>122.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>122.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>250 ng/mL</td><td rowspan=1 colspan=1>167.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>167.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>210.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>210.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>244.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>244.9</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>625 ng/mL</td><td rowspan=1 colspan=1>273.5</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>273.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>760 ng/mL</td><td rowspan=1 colspan=1>296.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>296.5</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=1 colspan=1>875 ng/mL</td><td rowspan=1 colspan=1>318.1</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>318.1</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.7%</td></tr><tr><td rowspan=1 colspan=1>1000 ng/mL</td><td rowspan=1 colspan=1>336.5</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>336.5</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.9%</td></tr></table>

# Qualitative Positive/Negative Results:

<table><tr><td rowspan=1 colspan=2>500 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SampleConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImimunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negafive</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>250 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>16 Pos/6 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>62 Pos/26 Neg</td></tr><tr><td rowspan=1 colspan=1>625 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>750 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>875 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>1000 ngimL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>SS</td><td rowspan=1 colspan=1>SS Positive</td></tr></table>

# Limit of Detection:

The lowest concentration that can be differentiated from the negative urine with $9 5 \%$ confidence is determined as $2 5 \Im \Im \mathrm { \Im m L }$ .

# Linearity:

Hitachi 717 Instrument: $0 - 2 0 0 0 { \mathfrak { a g } } / { \mathfrak { m } } { \mathbf { L } }$   
When comparing the result (y) and target $( \vec { \bf x } )$ value, using the least squares regression technique, the regression equation and correlation are as follow.   
$\mathbf { y } = 0 . 9 7 9 1 \mathbf { x } - 2 . 8 \overline { { 2 } } 8 9 , \mathbf { r } ^ { 3 } = 0 . \bar { 9 } 9 9 6$ Method Comparison - Clinical Samples:   
From a total of ninety-five (95) clinical unaltered samples Semi-Quantitative Data:   
$9 7 . 8 7 \%$ agreement with positive.   
$100 \%$ agreement with negative samples   
Qualitative Data:   
$9 7 . 8 7 \%$ agreement with positive,   
$100 \%$ agreement with negative samples

# Performance Characteristics Summary: continued Hitachi 717 Analyzer

Endogenous Compound Interference & Specificity & Cross-Reactivity: No significant undesired cross reactants or endogenous substance interference was observed.

# Summary:

The information provided in this pre-market notification demonstrates that the LZI Methamphetamine Enzyme Immmoassay at a cutoff value of $5 0 0 ~ \mathrm { \textmu g / m L }$ is substantially equivalent to the legally marketed predicate device for its general intended use. Substantial equivalence was demonstrated through comparison of intended use and physical properties to the commercially available predicate device as confirmed by chromatography/mass spectrometry (GC/MS or LC/MS), an independent analytical method. The information supplied in this pre-market notification provides reasonable assurance that the LZI Methamphetanine Enzyme Inmunoassay at a cutoff value of $5 0 0 ~ \mathrm { \pmb { n g / m L } }$ is safe and effective for its stated intended use.

Lin-Zhi International, Inc c/o Dr. Bernice Lin VP Operations 670 Almanor Avenue Sunnyvale, CA 94085

Re: k113661 Trade Name: LZI Methamphetamine Enzyme Immunoassay Regulation Number: 21 CFR $\ S 8 6 2 . 3 6 1 0$ EY Regulation Name: Methamphetamine Test System Regulatory Class: Class II Product Codes: LAF, DLJ, LAS Dated: December 12, 2011 Received: December 13, 2011

Dear Dr Lin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/34b5d601daa0a67da4c7bbdad3019c50744c8e9d1942e3c00a9daaa79bd91f4b.jpg)

Coupney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Premarket Notification

# Indications for Use Statement

Device Name:

# LZI Methamphetamine Enzyme Immunoassay LZI Methamphetamine Calibrators and Controls

# Indications for Use:

The LZI Methamphetamine Enzyme Immunoassay is intended for the qualitative and semiquantitative determination of d-methamphetamine in human urine, at the cutoff value of 500 ng/mL. The assay is designed for professional use with a number of automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS and LCMS or (2) permitting laboratories to establish quality control procedures.

The LZI Methamphetamine Drugs of Abuse (DAU) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the LZI Methamphetamine Erizyme Immunoassay at a cutoff value of $5 0 0 ~ \mathrm { { n g / m L } }$ .

The LZI Methamphetamine Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the Methamphetamine Enzyme Immunoassay at a cutoff value of $5 0 0 ~ \mathrm { { n g / m L } }$ .

The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or liquid chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method). Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive

AndOr

Prescription Use (21 CFR Part 801 Subpart D)

Over the Counter Use (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/cac4583f947355df1773e0f54ccd84616c693da6c28ed56bf015abe403677d33.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety